Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.

Cancer immunology, immunotherapy : CII - 6 Aug 2024

Park Changhee, Suh Koung Jin, Kim Se Hyun, Lee Kyung-Hun, Im Seock-Ah, Kim Min Hwan, Sohn Joohyuk, Jeong Jae Ho, Jung Kyung Hae, Lee Kyoung Eun, Park Yeon Hee, Kim Hee-Jun, Cho Eun Kyung, Choi In Sil, Noh Seung-Jae, Shin Inkyung, Cho Dae-Yeon, Kim Jee Hyun

Abstract excerpt

BACKGROUND: Biomarkers for predicting response to the immunotherapy and chemotherapy combination in breast cancer patients are not established. In this study, we report exploratory genomic and transcriptomic analyses of pretreatment tumor tissues from patients enrolled in phase II clinical trial of a combination of eribulin and nivolumab for HER-2-negative metastatic breast cancer (MBC) (KORNELIA trial,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Furans

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to Ketones

Share to Neoplasm Metastasis

Share to Nivolumab

Share to Receptor, ErbB-2

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 39105849
DOI: 10.1007/s00262-024-03782-7
PMCID: PMC11303363

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and transcriptomic profiles associated with response to eribulin and nivolumab combination in HER-2-negative metastatic breast cancer.PMID 39105849Read ↗

Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity Read ↗

Molecular intrinsic subtypes, genomic and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancersSemantic proximity Read ↗

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancersSemantic proximity Read ↗

Integrative Analysis of Homologous Recombination Repair Patterns Unveils Prognostic Signatures and Immunotherapeutic Insights in Breast CancerSemantic proximity Read ↗

Integrative analysis of homologous recombination repair patterns unveils prognostic signatures and immunotherapeutic insights in breast cancer.Semantic proximity Read ↗

Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.Semantic proximity Read ↗

Antigen-Presenting B-Cell Signature Predicts Response and Survival in HER2-Positive Breast CancerSemantic proximity Read ↗

Integrative Multiomic Profiling of Triple-Negative Breast Cancer for Identifying Suitable Therapies.Semantic proximity Read ↗

Prognostic analysis of patients with breast cancer based on tumor mutational burden and DNA damage repair genesSemantic proximity Read ↗

A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscapeSemantic proximity Read ↗

Emerging Protein Targets in Triple Negative Breast Cancer: Beyond Conventional TherapySemantic proximity Read ↗

Integrated tumor genomic and immune microenvironment analysis identifies predictive biomarkers associated with the efficacy of neoadjuvant therapy for triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.